Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL489205 | 1.00 | MME (1.00) | MMEMMP1 | |
| SCHEMBL6349761 | 0.90 | MME (1.00) | MMEMMP1 | |
| SCHEMBL6340259 | 0.90 | MME (0.82) | MMEMMP1 | |
| SCHEMBL5702547 | 0.84 | MME (0.72) | MMEMMP1 | |
| SCHEMBL6337481 | 0.81 | MME (0.68) | MMEMMP1 | |
| SCHEMBL6339711 | 0.81 | MME (0.68) | MMEMMP1 | |
| SCHEMBL6349925 | 0.81 | MME (0.68) | MME | |
| SCHEMBL8270265 | 0.80 | MME (0.67) | MMEMMP1 | |
| SCHEMBL5702694 | 0.80 | MME (0.67) | MME | |
| SCHEMBL7066246 | 0.80 | MME (0.66) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240342187-A1 | USE OF NEP INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DISORDERS | CURTAILS LLC (US) | 2024-10-17 | — | — | US | claimed |
| US-20240342188-A1 | Use of NEP Inhibitors for the Treatment of Laminitis | CURTAILS LLC (US) | 2024-10-17 | — | — | US | claimed |
| US-20230128032-A1 | Early Drug Interventions to Reduce COVID-19 Related Respiratory Distress, Need for Respirator Assist and Death | CURTAILS LLC (US) | 2023-04-27 | — | — | US | claimed |
| WO-2023018795-A1 | NEP INHIBITORS FOR THE TREATMENT OF LAMINITIS | CURTAILS LLC (US) | 2023-02-16 | — | — | WO | claimed |
| WO-2022265984-A1 | USE OF NEP INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DISORDERS | CURTAILS LLC (US) | 2022-12-22 | — | — | WO | claimed |
| US-20040106611-A1 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC | 2004-06-03 | — | — | US | claimed |
| US-6660756-B2 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC. | 2003-12-09 | — | — | US | claimed |
| US-20030105132-A1 | N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC. | 2003-06-05 | — | — | US | claimed |
| US-12209144-B2 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2025-01-28 | — | — | US | disclosed |
| CN-113166204-B | Cyclic peptides as inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK 9) for the treatment of metabolic disorders | 诺华股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-113166114-B | Cyclic tetramer compounds as inhibitors of proprotein convertase subtilisin/KEXIN type 9 (PCSK 9) for the treatment of metabolic disorders | 诺华股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20240342187-A1 | USE OF NEP INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DISORDERS | CURTAILS LLC (US) | 2024-10-17 | — | — | US | disclosed |
| US-20240342188-A1 | Use of NEP Inhibitors for the Treatment of Laminitis | CURTAILS LLC (US) | 2024-10-17 | — | — | US | disclosed |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
| US-20030125334-A1 | 5-HT receptor ligands and uses thereof | CHIANG PHOEBE (US) | 2003-07-03 | — | — | US | disclosed |
| US-20030105132-A1 | N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC. | 2003-06-05 | — | — | US | disclosed |
| US-20030105106-A1 | 5-HT receptor ligands and uses thereof | CHIANG PHOEBE (US) | 2003-06-05 | — | — | US | disclosed |
| WO-2003000663-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000666-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2002079143-A1 | N-PHENPROPYLCYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS NEP INHIBITORS FOR FSAD | PFIZER LIMITED (GB) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105132-A1 | N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PREP, ENGASE, ENPEP | MME 14/4885MMP1 871/4885 |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | MME 281/4885MMP1 2322/4885 |
| US-20030105106-A1 | 5-HT receptor ligands and uses thereof | HTR1A, HTR2A, HTR5A | MME 1405/4885MMP1 2757/4885 |
| US-12209144-B2 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | MME 125/4885MMP1 1421/4885 |
| US-20040106611-A1 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PREP, ENGASE, ENPEP | MME 15/4885MMP1 718/4885 |
| US-20240342188-A1 | Use of NEP Inhibitors for the Treatment of Laminitis | MME, REN, ACE | MME 1/4885MMP1 48/4885 |
| US-20030125334-A1 | 5-HT receptor ligands and uses thereof | HTR1A, HTR2A, HTR5A | MME 1405/4885MMP1 2757/4885 |
| US-20240342187-A1 | USE OF NEP INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DISORDERS | MME, REN, ACE | MME 1/4885MMP1 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.